Merck Expands Singapore Lab with Advanced Testing Capabilities

Merck is expanding its BioReliance laboratory in Singapore to strengthen analytical and biosafety testing services for biopharmaceutical companies across the Asia Pacific region.

The new facility, which will be over 1,000 square meters, will offer both Cell Line Characterization services and GMP next-generation sequencing (NGS) capabilities, making it the first BioReliance site in Asia Pacific to do so.

Merck's proprietary Blazar platform for rapid virus detection will also be available at the expanded facility.

The investment is aimed at supporting the region's growing biopharma industry with locally available contract testing capabilities, helping companies accelerate development timelines and meet evolving regulatory requirements.